Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Post by Pareto8020on Jun 26, 2021 10:51am
306 Views
Post# 33455920

Milestones - pick a card....any card.

Milestones - pick a card....any card.Unless Howard pulls another we can't control the process or timelines and lawyers are slow act again here is what they have put out there to achieve by end of July...


- Finalize due diligence and agree on terms with new organization in China
-Complete an additional licensing agreement for the SGLT2 inhibitor in new markets
- Secure non-dilutive funding through anticipated collaborations
- Finalize Tinyi agreement
- Complete Phase I clinical trial in China for the SGLT2 Inhibitor and advance to Phase II

Now you would think that SBM would have gotten a release date from Wanbang otherwise they wouldn't have it included it in the checklist.  So of all the milestones I think this one should be completed since it has already been 7 years and is overdue to start with and Wanbang likely gave SBM the timeframe the Phase I results would be ready for public consumption. 

I'd love to see them wrap up the animal use contract too since it is with 2 international companies and I get the impression they've split up the global rights so should be fairly substantial dollar value attached to it.  But for heavens sake just finalize something cause it is getting absurd the lack of news and contracts given the time periods they've had to execute on these.  
<< Previous
Bullboard Posts
Next >>